Added to YB: 2026-10-08
Pitch date: 2026-10-04
ADMA [bullish]
ADMA Biologics, Inc.
+11.42%
current return
Author Info
No bio for this author
Company Info
ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally.
Market Cap
$2.3B
Pitch Price
$9.63
Price Target
N/A
Dividend
N/A
EV/EBITDA
10.37
P/E
14.54
EV/Sales
4.58
Sector
Biotechnology
Category
growth
Free under $10 Ticker Biotech Quarter Review Tier 1 basket — strategic biotech and specialty pharma - ADMA Biologics, Inc.
ADMA (earnings): ADMA is a commercial compounder centered on ASCENIV, its main growth and margin driver. Q2 2026 revenue reached $124.4 million, including $102.9 million from ASCENIV, up 24% year over year; gross margin was 69%, and management reaffirmed 2026 revenue guidance of $530-$560 million. The case rests on continued execution rather than M&A, with ASCENIV concentration and plasma-supply complexity the main risks.
Read full article (1 min)